Browsing: Weight Loss

As a psychiatrist, I’ve seen the mental health benefits that go along with successful weight loss—improved mood, enhanced self-esteem, and reduced anxiety. And as a registered dietitian, Jenna Moore has witnessed the physical benefits firsthand. Medicines such as semaglutide and tirzepatide have produced a breakthrough in the treatment of obesity. Patients generally lose 15-20% of…

On August 5, Eli Lilly released its 2026 first-half performance report. One number took the entire pharmaceutical industry’s breath away: Tirzepatide — the glycemia-lowering version Mounjaro and the weight-loss version Zepbound — posted combined revenue of 27.693 billion US dollars in the first half of the year, representing an 88% year-on-year increase

Walking is one of the best things you can do for your health—but once it becomes routine, it may be time to make it more challenging. If you’re ready to level up, try turning your daily stroll into more of a workout. Whether you increase distance or add effort, even small adjustments can have a…

(Bloomberg) — Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split

Weight-loss medications have moved from medical conversations into mainstream culture, and outdoor advertising is becoming an important part of that shift

Though the influencer went from a size 20 to a size 12 after dropping 65 pounds, she admitted that there are still parts of her body she isn’t fully comfortable with showing publicly

Novo Nordisk A/S (NOVO) held its Q2 2026 earnings call on August 5, 2026, during which the Phase III failure of ziltivekimab in cardiovascular outcomes dominated the R&D discussion, , while management defended CagriSema’s competitive positioning versus tirzepatide and the outlined the next wave of obesity assets led by zenagamtide

Investing.com — Eli Lilly shares jumped more than 6% after the market opened on Wednesday as the U.S. pharma giant raised its annual revenue guidance fueled by continued demand for its popular weight-loss and diabetes drugs

S.C. – Medicare has expanded coverage for glucagon-like peptide-1, or GLP-1, weight loss medications, a decision that health providers say is already driving more patients to seek treatment

Uncover the next big thing with 19 elite penny stocks that balance risk and reward